Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $150

Benzinga Newsdesk www.benzinga.com Negative 95.2%

Neg 95.2% Neu 0% Pos 0%

Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $170 to $150.